HLA-B27, antinuclear antibodies and drug-induced agranulocytosis.
Eight female patients with drug-induced agranulocytosis (five patients with definite seropositive rheumatoid arthritis (RA), three patients with upper respiratory infections) were studied for the presence of HLA-B27 and antinuclear antibodies (ANA). Five of eight patients were found to be HLA-B27 positive and all RA patients had ANA in their serum. The frequency of HLA-B27 and ANA was found to be significantly different from control groups. It is concluded that the occurrence of HLA-B27 and ANA was found to be significantly different from control groups. It is concluded that the occurrence of HLA-B27 in female patients with seropositive RA (especially in those with ANA) and of HLA-B27 alone in other individuals could reflect an increased risk for drug-induced agranulocytosis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000097:blood* / Q000139:chemically induced; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects
D000974:Antibodies, Antinuclear; D006680:HLA Antigens; D011720:Pyrazoles; D007978:Levamisole